Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
21.96
+0.29 (1.34%)
Mar 7, 2025, 4:00 PM EST - Market closed
Catalyst Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 491.73 | 398.2 | 214.2 | 140.83 | 119.07 | Upgrade
|
| Revenue Growth (YoY) | 23.49% | 85.90% | 52.10% | 18.27% | 16.39% | Upgrade
|
| Cost of Revenue | 70.62 | 53.45 | 36.12 | 38.82 | 33.54 | Upgrade
|
| Gross Profit | 421.11 | 344.76 | 178.08 | 102.01 | 85.54 | Upgrade
|
| Selling, General & Admin | 177.74 | 133.71 | 57.09 | 49.63 | 44.23 | Upgrade
|
| Research & Development | 10.87 | 91.67 | 18.06 | - | - | Upgrade
|
| Operating Expenses | 225.99 | 257.94 | 76.24 | 49.63 | 44.23 | Upgrade
|
| Operating Income | 195.12 | 86.81 | 101.84 | 52.39 | 41.3 | Upgrade
|
| Interest & Investment Income | 16.06 | 4.68 | - | 0.28 | 0.59 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 2.88 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 211.19 | 91.49 | 104.72 | 52.67 | 41.89 | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.08 | 3.02 | - | - | - | Upgrade
|
| Pretax Income | 216.26 | 94.51 | 104.72 | 52.67 | 41.89 | Upgrade
|
| Income Tax Expense | 52.37 | 23.1 | 21.64 | 13.19 | -33.09 | Upgrade
|
| Net Income | 163.89 | 71.41 | 83.08 | 39.48 | 74.98 | Upgrade
|
| Net Income to Common | 163.89 | 71.41 | 83.08 | 39.48 | 74.98 | Upgrade
|
| Net Income Growth | 129.50% | -14.05% | 110.42% | -47.35% | 135.24% | Upgrade
|
| Shares Outstanding (Basic) | 118 | 106 | 103 | 103 | 104 | Upgrade
|
| Shares Outstanding (Diluted) | 125 | 114 | 111 | 108 | 106 | Upgrade
|
| Shares Change (YoY) | 9.84% | 2.13% | 3.32% | 1.46% | 0.21% | Upgrade
|
| EPS (Basic) | 1.38 | 0.67 | 0.80 | 0.38 | 0.72 | Upgrade
|
| EPS (Diluted) | 1.31 | 0.63 | 0.75 | 0.37 | 0.71 | Upgrade
|
| EPS Growth | 107.94% | -16.00% | 102.70% | -47.89% | 136.67% | Upgrade
|
| Free Cash Flow | 239.25 | -54.92 | 106.02 | 59.35 | 45.02 | Upgrade
|
| Free Cash Flow Per Share | 1.91 | -0.48 | 0.95 | 0.55 | 0.42 | Upgrade
|
| Gross Margin | 85.64% | 86.58% | 83.14% | 72.44% | 71.84% | Upgrade
|
| Operating Margin | 39.68% | 21.80% | 47.54% | 37.20% | 34.69% | Upgrade
|
| Profit Margin | 33.33% | 17.93% | 38.79% | 28.03% | 62.97% | Upgrade
|
| Free Cash Flow Margin | 48.65% | -13.79% | 49.49% | 42.14% | 37.81% | Upgrade
|
| EBITDA | 232.9 | 119.69 | 103.08 | 52.58 | 41.4 | Upgrade
|
| EBITDA Margin | 47.36% | 30.06% | 48.12% | 37.33% | 34.76% | Upgrade
|
| D&A For EBITDA | 37.77 | 32.88 | 1.24 | 0.19 | 0.09 | Upgrade
|
| EBIT | 195.12 | 86.81 | 101.84 | 52.39 | 41.3 | Upgrade
|
| EBIT Margin | 39.68% | 21.80% | 47.54% | 37.20% | 34.69% | Upgrade
|
| Effective Tax Rate | 24.22% | 24.44% | 20.66% | 25.03% | - | Upgrade
|
| Revenue as Reported | 491.73 | 398.2 | 214.2 | 140.83 | 119.07 | Upgrade
|
| Advertising Expenses | 10 | 9.1 | 3.3 | 2.9 | 2.5 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.